Oncogene alterations in endometrial carcinoma

Matthew P. Borst, Vicki V. Baker, Diane Dixon, Kenneth D Hatch, Hugh M. Shingleton, Donald M. Miller

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The neu oncogene codes for a cell surface protein that has a high degree of homology with the epidermal growth factor receptor. Amplification of this oncogene in breast carcinoma and ovarian carcinoma is correlated with a poorer prognosis. The c-myc oncogene codes for a DNA binding protein and is believed to regulate cellular proliferation. Sixteen primary endometrial adenocarcinomas were analyzed for c-myc and c-neu amplification. Eleven of sixteen tumor samples exhibited amplification of the neu gene. Four of these eleven patients died of disease an average of 16 months after diagnosis. The five patients without tumor amplification of the c-neu gene have been followed an average of 31.2 months without evidence of recurrent disease. Ten of fifteen tumor samples exhibited amplification of the c-myc gene. Five of the ten patients died of disease an average of 13.4 months after diagnosis. The remaining five patients have been followed for an average of 31.2 months and are free of disease. Six of the sixteen tumor specimens exhibited amplification of the both c-neu and c-myc genes, and four of these patients died of recurrent disease. Amplification of the c-neu or c-myc oncogene correlated with advanced-stage disease and poorly differentiated lesions, suggesting that oncogene amplification may predict biologically aggressive adenocarcinomas of the endometrium.

Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalGynecologic Oncology
Volume38
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Oncogenes
myc Genes
erbB-2 Genes
Neoplasms
Adenocarcinoma
DNA-Binding Proteins
Endometrium
Epidermal Growth Factor Receptor
Membrane Proteins
Cell Proliferation
Breast Neoplasms
Carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Borst, M. P., Baker, V. V., Dixon, D., Hatch, K. D., Shingleton, H. M., & Miller, D. M. (1990). Oncogene alterations in endometrial carcinoma. Gynecologic Oncology, 38(3), 364-366. https://doi.org/10.1016/0090-8258(90)90074-U

Oncogene alterations in endometrial carcinoma. / Borst, Matthew P.; Baker, Vicki V.; Dixon, Diane; Hatch, Kenneth D; Shingleton, Hugh M.; Miller, Donald M.

In: Gynecologic Oncology, Vol. 38, No. 3, 1990, p. 364-366.

Research output: Contribution to journalArticle

Borst, MP, Baker, VV, Dixon, D, Hatch, KD, Shingleton, HM & Miller, DM 1990, 'Oncogene alterations in endometrial carcinoma', Gynecologic Oncology, vol. 38, no. 3, pp. 364-366. https://doi.org/10.1016/0090-8258(90)90074-U
Borst, Matthew P. ; Baker, Vicki V. ; Dixon, Diane ; Hatch, Kenneth D ; Shingleton, Hugh M. ; Miller, Donald M. / Oncogene alterations in endometrial carcinoma. In: Gynecologic Oncology. 1990 ; Vol. 38, No. 3. pp. 364-366.
@article{f492d0bc829f4ed4ae9901a713114f21,
title = "Oncogene alterations in endometrial carcinoma",
abstract = "The neu oncogene codes for a cell surface protein that has a high degree of homology with the epidermal growth factor receptor. Amplification of this oncogene in breast carcinoma and ovarian carcinoma is correlated with a poorer prognosis. The c-myc oncogene codes for a DNA binding protein and is believed to regulate cellular proliferation. Sixteen primary endometrial adenocarcinomas were analyzed for c-myc and c-neu amplification. Eleven of sixteen tumor samples exhibited amplification of the neu gene. Four of these eleven patients died of disease an average of 16 months after diagnosis. The five patients without tumor amplification of the c-neu gene have been followed an average of 31.2 months without evidence of recurrent disease. Ten of fifteen tumor samples exhibited amplification of the c-myc gene. Five of the ten patients died of disease an average of 13.4 months after diagnosis. The remaining five patients have been followed for an average of 31.2 months and are free of disease. Six of the sixteen tumor specimens exhibited amplification of the both c-neu and c-myc genes, and four of these patients died of recurrent disease. Amplification of the c-neu or c-myc oncogene correlated with advanced-stage disease and poorly differentiated lesions, suggesting that oncogene amplification may predict biologically aggressive adenocarcinomas of the endometrium.",
author = "Borst, {Matthew P.} and Baker, {Vicki V.} and Diane Dixon and Hatch, {Kenneth D} and Shingleton, {Hugh M.} and Miller, {Donald M.}",
year = "1990",
doi = "10.1016/0090-8258(90)90074-U",
language = "English (US)",
volume = "38",
pages = "364--366",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Oncogene alterations in endometrial carcinoma

AU - Borst, Matthew P.

AU - Baker, Vicki V.

AU - Dixon, Diane

AU - Hatch, Kenneth D

AU - Shingleton, Hugh M.

AU - Miller, Donald M.

PY - 1990

Y1 - 1990

N2 - The neu oncogene codes for a cell surface protein that has a high degree of homology with the epidermal growth factor receptor. Amplification of this oncogene in breast carcinoma and ovarian carcinoma is correlated with a poorer prognosis. The c-myc oncogene codes for a DNA binding protein and is believed to regulate cellular proliferation. Sixteen primary endometrial adenocarcinomas were analyzed for c-myc and c-neu amplification. Eleven of sixteen tumor samples exhibited amplification of the neu gene. Four of these eleven patients died of disease an average of 16 months after diagnosis. The five patients without tumor amplification of the c-neu gene have been followed an average of 31.2 months without evidence of recurrent disease. Ten of fifteen tumor samples exhibited amplification of the c-myc gene. Five of the ten patients died of disease an average of 13.4 months after diagnosis. The remaining five patients have been followed for an average of 31.2 months and are free of disease. Six of the sixteen tumor specimens exhibited amplification of the both c-neu and c-myc genes, and four of these patients died of recurrent disease. Amplification of the c-neu or c-myc oncogene correlated with advanced-stage disease and poorly differentiated lesions, suggesting that oncogene amplification may predict biologically aggressive adenocarcinomas of the endometrium.

AB - The neu oncogene codes for a cell surface protein that has a high degree of homology with the epidermal growth factor receptor. Amplification of this oncogene in breast carcinoma and ovarian carcinoma is correlated with a poorer prognosis. The c-myc oncogene codes for a DNA binding protein and is believed to regulate cellular proliferation. Sixteen primary endometrial adenocarcinomas were analyzed for c-myc and c-neu amplification. Eleven of sixteen tumor samples exhibited amplification of the neu gene. Four of these eleven patients died of disease an average of 16 months after diagnosis. The five patients without tumor amplification of the c-neu gene have been followed an average of 31.2 months without evidence of recurrent disease. Ten of fifteen tumor samples exhibited amplification of the c-myc gene. Five of the ten patients died of disease an average of 13.4 months after diagnosis. The remaining five patients have been followed for an average of 31.2 months and are free of disease. Six of the sixteen tumor specimens exhibited amplification of the both c-neu and c-myc genes, and four of these patients died of recurrent disease. Amplification of the c-neu or c-myc oncogene correlated with advanced-stage disease and poorly differentiated lesions, suggesting that oncogene amplification may predict biologically aggressive adenocarcinomas of the endometrium.

UR - http://www.scopus.com/inward/record.url?scp=0025129959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025129959&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90074-U

DO - 10.1016/0090-8258(90)90074-U

M3 - Article

C2 - 2227549

AN - SCOPUS:0025129959

VL - 38

SP - 364

EP - 366

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -